Psilocybin Myths and Facts

Last updated: July 2, 2026 · Reviewed against the editorial policy

Education only. This page is for harm reduction education. It is not medical advice and does not encourage psilocybin use. Psilocybin is illegal in most places — see legal status.

Plain-language summary

Psilocybin attracts strong claims on both sides. Some people say one trip will drive you insane. Others say mushrooms are totally safe because they are natural. The research supports neither extreme. This page takes ten common myths and checks each one against published studies. The short version: psilocybin is not physically addictive and does not "rot" the brain, but bad trips are real, the law does not care that it is natural, and promising therapy trials do not make self-treatment safe.

Myth 1: One trip can make you permanently insane

Fact: Lasting psychosis after psilocybin is rare. Large population studies have not found that psychedelic use raises rates of mental illness.[1] A study of over 130,000 US adults found no link between past psychedelic use and higher rates of mental health problems.[1]

But "rare" is not "never." People with a personal or family history of a psychotic illness such as schizophrenia seem to face higher risk. That is why trials screen them out.[2] The honest summary: one trip will almost surely not make a healthy person insane. But psilocybin is a bad bet for people with psychosis risk. See our risks page for who should take the most care.

Myth 2: Psilocybin is physically addictive

Fact: Psilocybin does not cause physical dependence. There is no withdrawal, and animals do not reliably self-dose it the way they do with cocaine, opioids, or nicotine.[3] A close review of its abuse potential found psilocybin ranks far lower than typical drugs of abuse.[3]

Part of the reason is tolerance: taking psilocybin two days in a row sharply weakens the effect. That curbs heavy daily use. Still, "not addictive" does not mean "harmless." People can use it in risky ways, at bad times, or in spite of health warnings.

Myth 3: It's legal because it's natural

Fact: Being natural has no legal weight. In the United States, psilocybin and psilocin are Schedule I drugs under federal law, the strictest class.[3] Having psilocybin mushrooms is a crime in most of the country and most of the world.

Some US cities and states have decriminalized it or set up legal programs. But that is not the same as legal, and none of it changes federal law. The details shift often — see our legal status page for the current picture. And plenty of natural things are still risky or illegal. "Natural" tells you nothing about safety or law.

Myth 4: You can't have a bad trip if you're happy

Fact: A good mood helps, but it is no promise. In a survey of nearly 2,000 people who had a hard psilocybin trip, many were seasoned users, and 39% rated it among the most testing events of their lives.[4] Dose was one of the strongest signs of how hard it got — more so than mood alone.[4]

Mindset and setting — set and setting — clearly shape the odds, and an uneasy place makes hard moments more likely.[2] But a hard trip can happen even in good conditions. That is why harm-reduction guides stress prep work and a sober trip sitter rather than promising a good time.

Myth 5: Mushrooms rot your brain (or make it bleed)

Fact: There is no evidence that psilocybin kills brain cells, causes bleeding in the brain, or "rots" anything. The old story that psychedelics leave holes in the brain is a myth, not science. Psilocin, the active form of psilocybin, works by briefly turning on serotonin 5-HT2A receptors. It does not harm the brain at the doses people take.[5]

Physically, psilocybin ranks among the least toxic street drugs, with small effects on heart rate and blood pressure during the trip.[5] The real risks are elsewhere: accidents during the trip, eating the wrong mushroom, drug mixing, and mental distress. Our effects page covers what really happens in the brain and body.

Myth 6: Microdosing is proven safe and effective

Fact: Not proven — either way. Microdosing means taking doses too small to cause a trip, usually a few times a week. Users report better mood and focus, but careful research keeps finding a catch: in a large self-blinded trial, people who took a fake pill without knowing it improved about as much as people who took real microdoses.[6] That points to belief, not the drug, driving much of the reported gain.

Long-term safety data is also thin. Questions remain open, such as concerns about turning on serotonin receptors so often over months or years. "Unproven" is the right word — the trials to settle it have not been done. See clinical research for what studies do and do not show.

Myth 7: Psilocybin therapy means it's safe to self-treat depression

Fact: Trial results do not carry over to solo use. In studies where psilocybin eased depression and anxiety — such as the 2016 trial in patients with life-threatening cancer — people were screened by doctors, prepared over several sessions, given a lab-checked dose, watched by two trained guides for the whole session, and followed up after.[7]

Self-treatment has none of those safeguards. No screening for psychosis risk or heart problems. No known dose. No one to help if things go wrong. And someone in a depression crisis is just the person a hard trip can hit hardest.[4] Promising research is a reason to fund more research, not a green light to self-medicate. If you are struggling, the 988 Lifeline (below) is there right now.

Myth 8: You can't overdose on mushrooms

Fact: It depends what "overdose" means. Deaths from psilocybin alone are very rare, because the deadly dose is far above any common dose.[3] But taking too much for your situation is easy, and it matters. High doses bring more fear, confusion, and risky behavior.[4] People have been hurt during trips that got too intense.

There is also a deadlier trap: eating the wrong mushroom. Look-alike species that hold amatoxins can destroy the liver. If someone gets violently ill hours after eating a mushroom, treat it as an emergency — our emergencies page explains the warning signs.

Myth 9: Flashbacks happen to everyone who trips

Fact: Most people never have one. Brief returns of trip-like visuals can happen, and a small number of people develop a lasting form called hallucinogen persisting perception disorder (HPPD). A review of five decades of research found HPPD is real but rare, and its causes are still not well understood.[8]

Pooled data from controlled psilocybin studies found no cases of HPPD among screened, watched people.[9] Risk seems higher with heavy use and past conditions. Learn more on our HPPD page.

Myth 10: Tolerance means it works better every day

Fact: The opposite. Psilocybin tolerance builds fast — taking it again within a few days gives a much weaker effect, because serotonin 5-HT2A receptors adjust quickly.[5] Tolerance takes about one to two weeks to reset, and it carries over to related drugs like LSD (cross-tolerance).

Some people meet a weak second day by taking much more. That mostly buys a longer, rougher body load and less steady effects, not a repeat of day one. Fast tolerance is also one of the drug reasons psilocybin scores low on addiction.[3]

Need help right now?

  • Medical emergency (US): call 911.
  • Poison Control (US): 1-800-222-1222 — free, confidential, 24/7.
  • Fireside Project (psychedelic peer support line, US): call or text 62-FIRESIDE (623-473-7433).
  • 988 Suicide & Crisis Lifeline (US): call or text 988.

References

  1. Krebs TS, Johansen PØ. Psychedelics and mental health: a population study. PLoS ONE. 2013;8(8):e63972.
  2. Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology. 2008;22(6):603-620.
  3. Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018;142:143-166.
  4. Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. Journal of Psychopharmacology. 2016;30(12):1268-1278.
  5. Nichols DE. Psychedelics. Pharmacological Reviews. 2016;68(2):264-355.
  6. Szigeti B, Kartner L, Blemings A, et al. Self-blinding citizen science to explore psychedelic microdosing. eLife. 2021;10:e62878.
  7. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. Journal of Psychopharmacology. 2016;30(12):1181-1197.
  8. Halpern JH, Pope HG Jr. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug and Alcohol Dependence. 2003;69(2):109-119.
  9. Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology. 2011;25(11):1434-1452.

About the author

By Shane Hellmrich. Shane studied Health Promotion at Curtin University, with coursework in Human Biology, Psychology, Epidemiology, and Public Relations, and has over 20 years in the health industry. Content is reviewed against our editorial policy.